Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza

Antimicrobial Agents and Chemotherapy
S O AliRaburn M Mallory

Abstract

We evaluated MEDI8852, a human IgG1 monoclonal antibody that binds a highly conserved influenza A hemagglutinin stalk epitope, in outpatients with uncomplicated influenza A infection. A total of 126 subjects aged 18 to 65 years were enrolled during the 2015 to 2016 Northern and 2016 Southern Hemisphere seasons. Subjects with symptom onset ≤5 days before dosing were randomized to four cohorts: 750 mg (cohort 1) or 3,000 mg (cohort 2) MEDI8852 (single intravenous infusion) plus 75 mg oseltamivir, placebo plus 75 mg oseltamivir (cohort 3), and 3,000 mg MEDI8852 alone (cohort 4). Subjects were monitored through day 10 for solicited influenza symptoms, day 28 for adverse events (AEs), and day 101 for serious AEs and AEs of special interest. Nasopharyngeal samples were collected through day 7 for confirmation of influenza A infection, viral shedding, and oseltamivir and MEDI8852 susceptibility. Slightly more AEs were reported in subjects receiving MEDI8852 (cohorts 1, 2, and 4 combined: 39/93, 41.9%) than oseltamivir only (cohort 3: 10/32, 31.3%). Most AEs were mild or moderate. The most common AE was bronchitis (11/93, 11.8%; 1/32, 3.1%). The median (range) decrease in viral shedding (log10 virus genome copies/ml) was similar betwee...Continue Reading

References

Dec 21, 2002·The Journal of Antimicrobial Chemotherapy·F Y AokiUNKNOWN IMPACT Study Group
Oct 3, 2009·Vaccine·Pierre J T De VilliersUNKNOWN LAIV Elderly Study Trial Network
Jul 31, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Janice K LouieTimothy M Uyeki
Aug 30, 2013·Science Translational Medicine·Surender KhuranaHana Golding
Sep 2, 2015·Human Vaccines & Immunotherapeutics·Po-Ying Chan-Hui, Kristine M Swiderek
May 22, 2016·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Shobana Balasingam, Annelies Wilder-Smith
Oct 19, 2016·Trends in Microbiology·Boopathy RamakrishnanRam Sasisekharan
Mar 3, 2017·Bulletin of the World Health Organization·Erin SparrowSiranda Torvaldsen
Aug 29, 2017·Biologicals : Journal of the International Association of Biological Standardization·Raburn M MalloryLeo Tseng

❮ Previous
Next ❯

Citations

Jun 21, 2019·Vaccines·Erasmus KoteyMunir Iqbal
Dec 31, 2019·Pediatric Transplantation·Annabelle de St Maurice, Natasha Halasa
Jun 28, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Adam McNeeElma Tchilian
Mar 9, 2019·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Tianyu NiuDanqing Song
Aug 2, 2019·Current Drug Targets·Doreen Szollosi, Ashley Bill
Dec 5, 2020·Journal of Controlled Release : Official Journal of the Controlled Release Society·Samuel K LaiRaymond J Pickles
Jul 20, 2019·Antiviral Research·Koen Sedeyn, Xavier Saelens
Dec 15, 2020·Advanced Drug Delivery Reviews·Carlos Cruz-TeranSamuel K Lai
Oct 26, 2020·Drug Discovery Today·Rick HeidaHenderik W Frijlink
Nov 22, 2020·Drug Discovery Today·Hershna Patel, Andreas Kukol
Dec 18, 2020·Expert Opinion on Pharmacotherapy·Qiao ZhangShuwen Liu
Apr 8, 2021·Nature Reviews. Microbiology·Tim FlerlageStacey Schultz-Cherry
Dec 6, 2020·Seminars in Immunology·Simone PecettaAnja Seubert
May 24, 2021·Drug Discovery Today·Zeenat A ShyrWei Zheng
Jun 5, 2021·Cell·Davide CortiDavid Veesler
Sep 27, 2021·International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases·Philippe BuchyEskild Petersen

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.